

Global NASH Drug Pipeline Market Growth 2023-2029

<https://marketpublishers.com/r/GDAF1654569CEN.html>

Date: March 2023

Pages: 121

Price: US\$ 3,660.00 (Single User License)

ID: GDAF1654569CEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

LPI (LP Information)' newest research report, the "NASH Drug Pipeline Industry Forecast" looks at past sales and reviews total world NASH Drug Pipeline sales in 2022, providing a comprehensive analysis by region and market sector of projected NASH Drug Pipeline sales for 2023 through 2029. With NASH Drug Pipeline sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world NASH Drug Pipeline industry.

This Insight Report provides a comprehensive analysis of the global NASH Drug Pipeline landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on NASH Drug Pipeline portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global NASH Drug Pipeline market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for NASH Drug Pipeline and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global NASH Drug Pipeline.

The global NASH Drug Pipeline market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for NASH Drug Pipeline is estimated to increase from US\$ million

in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for NASH Drug Pipeline is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for NASH Drug Pipeline is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key NASH Drug Pipeline players cover Intercept, Genfit, Allergan, Madrigal, Immuron, Galectin, Gilead, 89bio Inc and ABIONYX Pharma SA, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of NASH Drug Pipeline market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

By Mechanism of Action

Protease Inhibitor

Immunomodulatory

Multiple Kinase Inhibitor

By Molecule Types

Small molecule

Stem Cell Therapy

Gene Therapy

By Route of Administration:

Inhalation

Intravenous

Oral

Subcutaneous

Segmentation by application

Clinical

Academic Research

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Intercept

Genfit

Allergan

Madrigal

Immuron

Galectin

Gilead

89bio Inc

ABIONYX Pharma SA

Abivax SA

Abliva AB

Acquist Therapeutics

AdAlta Ltd

Afimmune Biopharma Ltd

Zhejiang Doer Biologics Corp

Dicerna Pharmaceuticals Inc

ChemomAb Ltd

DURECT Corp

Eli Lilly and Co

Enanta Pharmaceuticals Inc

EncuraGen Inc

Engitix Ltd

Heprotech Inc

Hinova Pharmaceuticals Inc

HK inno.N Corp

HotSpot Therapeutics Inc

Key Questions Addressed in this Report

What is the 10-year outlook for the global NASH Drug Pipeline market?

What factors are driving NASH Drug Pipeline market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do NASH Drug Pipeline market opportunities vary by end market size?

How does NASH Drug Pipeline break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global NASH Drug Pipeline Annual Sales 2018-2029
 - 2.1.2 World Current & Future Analysis for NASH Drug Pipeline by Geographic Region, 2018, 2022 & 2029
 - 2.1.3 World Current & Future Analysis for NASH Drug Pipeline by Country/Region, 2018, 2022 & 2029
- 2.2 NASH Drug Pipeline Segment by Type
 - 2.2.1 Protease Inhibitor
 - 2.2.2 Immunomodulatory
 - 2.2.3 Multiple Kinase Inhibitor
- 2.3 NASH Drug Pipeline Sales by Type
 - 2.3.1 Global NASH Drug Pipeline Sales Market Share by Type (2018-2023)
 - 2.3.2 Global NASH Drug Pipeline Revenue and Market Share by Type (2018-2023)
 - 2.3.3 Global NASH Drug Pipeline Sale Price by Type (2018-2023)
- 2.4 NASH Drug Pipeline Segment by Application
 - 2.4.1 Clinical
 - 2.4.2 Academic Research
- 2.5 NASH Drug Pipeline Sales by Application
 - 2.5.1 Global NASH Drug Pipeline Sale Market Share by Application (2018-2023)
 - 2.5.2 Global NASH Drug Pipeline Revenue and Market Share by Application (2018-2023)
 - 2.5.3 Global NASH Drug Pipeline Sale Price by Application (2018-2023)

3 GLOBAL NASH DRUG PIPELINE BY COMPANY

- 3.1 Global NASH Drug Pipeline Breakdown Data by Company
 - 3.1.1 Global NASH Drug Pipeline Annual Sales by Company (2018-2023)
 - 3.1.2 Global NASH Drug Pipeline Sales Market Share by Company (2018-2023)
- 3.2 Global NASH Drug Pipeline Annual Revenue by Company (2018-2023)
 - 3.2.1 Global NASH Drug Pipeline Revenue by Company (2018-2023)
 - 3.2.2 Global NASH Drug Pipeline Revenue Market Share by Company (2018-2023)
- 3.3 Global NASH Drug Pipeline Sale Price by Company
- 3.4 Key Manufacturers NASH Drug Pipeline Producing Area Distribution, Sales Area, Product Type
 - 3.4.1 Key Manufacturers NASH Drug Pipeline Product Location Distribution
 - 3.4.2 Players NASH Drug Pipeline Products Offered
- 3.5 Market Concentration Rate Analysis
 - 3.5.1 Competition Landscape Analysis
 - 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR NASH DRUG PIPELINE BY GEOGRAPHIC REGION

- 4.1 World Historic NASH Drug Pipeline Market Size by Geographic Region (2018-2023)
 - 4.1.1 Global NASH Drug Pipeline Annual Sales by Geographic Region (2018-2023)
 - 4.1.2 Global NASH Drug Pipeline Annual Revenue by Geographic Region (2018-2023)
- 4.2 World Historic NASH Drug Pipeline Market Size by Country/Region (2018-2023)
 - 4.2.1 Global NASH Drug Pipeline Annual Sales by Country/Region (2018-2023)
 - 4.2.2 Global NASH Drug Pipeline Annual Revenue by Country/Region (2018-2023)
- 4.3 Americas NASH Drug Pipeline Sales Growth
- 4.4 APAC NASH Drug Pipeline Sales Growth
- 4.5 Europe NASH Drug Pipeline Sales Growth
- 4.6 Middle East & Africa NASH Drug Pipeline Sales Growth

5 AMERICAS

- 5.1 Americas NASH Drug Pipeline Sales by Country
 - 5.1.1 Americas NASH Drug Pipeline Sales by Country (2018-2023)
 - 5.1.2 Americas NASH Drug Pipeline Revenue by Country (2018-2023)
- 5.2 Americas NASH Drug Pipeline Sales by Type
- 5.3 Americas NASH Drug Pipeline Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC NASH Drug Pipeline Sales by Region

6.1.1 APAC NASH Drug Pipeline Sales by Region (2018-2023)

6.1.2 APAC NASH Drug Pipeline Revenue by Region (2018-2023)

6.2 APAC NASH Drug Pipeline Sales by Type

6.3 APAC NASH Drug Pipeline Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe NASH Drug Pipeline by Country

7.1.1 Europe NASH Drug Pipeline Sales by Country (2018-2023)

7.1.2 Europe NASH Drug Pipeline Revenue by Country (2018-2023)

7.2 Europe NASH Drug Pipeline Sales by Type

7.3 Europe NASH Drug Pipeline Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa NASH Drug Pipeline by Country

8.1.1 Middle East & Africa NASH Drug Pipeline Sales by Country (2018-2023)

8.1.2 Middle East & Africa NASH Drug Pipeline Revenue by Country (2018-2023)

8.2 Middle East & Africa NASH Drug Pipeline Sales by Type

8.3 Middle East & Africa NASH Drug Pipeline Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of NASH Drug Pipeline

10.3 Manufacturing Process Analysis of NASH Drug Pipeline

10.4 Industry Chain Structure of NASH Drug Pipeline

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 NASH Drug Pipeline Distributors

11.3 NASH Drug Pipeline Customer

12 WORLD FORECAST REVIEW FOR NASH DRUG PIPELINE BY GEOGRAPHIC REGION

12.1 Global NASH Drug Pipeline Market Size Forecast by Region

12.1.1 Global NASH Drug Pipeline Forecast by Region (2024-2029)

12.1.2 Global NASH Drug Pipeline Annual Revenue Forecast by Region (2024-2029)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global NASH Drug Pipeline Forecast by Type

12.7 Global NASH Drug Pipeline Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Intercept

13.1.1 Intercept Company Information

13.1.2 Intercept NASH Drug Pipeline Product Portfolios and Specifications

13.1.3 Intercept NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)

13.1.4 Intercept Main Business Overview

13.1.5 Intercept Latest Developments

13.2 Genfit

13.2.1 Genfit Company Information

13.2.2 Genfit NASH Drug Pipeline Product Portfolios and Specifications

13.2.3 Genfit NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)

13.2.4 Genfit Main Business Overview

13.2.5 Genfit Latest Developments

13.3 Allergan

13.3.1 Allergan Company Information

13.3.2 Allergan NASH Drug Pipeline Product Portfolios and Specifications

13.3.3 Allergan NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)

13.3.4 Allergan Main Business Overview

13.3.5 Allergan Latest Developments

13.4 Madrigal

13.4.1 Madrigal Company Information

13.4.2 Madrigal NASH Drug Pipeline Product Portfolios and Specifications

13.4.3 Madrigal NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)

13.4.4 Madrigal Main Business Overview

13.4.5 Madrigal Latest Developments

13.5 Immuron

13.5.1 Immuron Company Information

13.5.2 Immuron NASH Drug Pipeline Product Portfolios and Specifications

13.5.3 Immuron NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)

13.5.4 Immuron Main Business Overview

13.5.5 Immuron Latest Developments

13.6 Galectin

13.6.1 Galectin Company Information

13.6.2 Galectin NASH Drug Pipeline Product Portfolios and Specifications

13.6.3 Galectin NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)

13.6.4 Galectin Main Business Overview

13.6.5 Galectin Latest Developments

13.7 Gilead

13.7.1 Gilead Company Information

13.7.2 Gilead NASH Drug Pipeline Product Portfolios and Specifications

13.7.3 Gilead NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)

13.7.4 Gilead Main Business Overview

13.7.5 Gilead Latest Developments

13.8 89bio Inc

13.8.1 89bio Inc Company Information

13.8.2 89bio Inc NASH Drug Pipeline Product Portfolios and Specifications

13.8.3 89bio Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)

13.8.4 89bio Inc Main Business Overview

13.8.5 89bio Inc Latest Developments

13.9 ABIONYX Pharma SA

13.9.1 ABIONYX Pharma SA Company Information

13.9.2 ABIONYX Pharma SA NASH Drug Pipeline Product Portfolios and Specifications

13.9.3 ABIONYX Pharma SA NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)

13.9.4 ABIONYX Pharma SA Main Business Overview

13.9.5 ABIONYX Pharma SA Latest Developments

13.10 Abivax SA

13.10.1 Abivax SA Company Information

13.10.2 Abivax SA NASH Drug Pipeline Product Portfolios and Specifications

13.10.3 Abivax SA NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)

13.10.4 Abivax SA Main Business Overview

13.10.5 Abivax SA Latest Developments

13.11 Abliva AB

13.11.1 Abliva AB Company Information

13.11.2 Abliva AB NASH Drug Pipeline Product Portfolios and Specifications

13.11.3 Abliva AB NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)

13.11.4 Abliva AB Main Business Overview

13.11.5 Abliva AB Latest Developments

13.12 Acquist Therapeutics

13.12.1 Acquist Therapeutics Company Information

13.12.2 Acquist Therapeutics NASH Drug Pipeline Product Portfolios and Specifications

13.12.3 Acquist Therapeutics NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)

13.12.4 Acquist Therapeutics Main Business Overview

13.12.5 Acquist Therapeutics Latest Developments

13.13 AdAlta Ltd

13.13.1 AdAlta Ltd Company Information

13.13.2 AdAlta Ltd NASH Drug Pipeline Product Portfolios and Specifications

13.13.3 AdAlta Ltd NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)

13.13.4 AdAlta Ltd Main Business Overview

13.13.5 AdAlta Ltd Latest Developments

13.14 Afimmune Biopharma Ltd

13.14.1 Afimmune Biopharma Ltd Company Information

13.14.2 Afimmune Biopharma Ltd NASH Drug Pipeline Product Portfolios and Specifications

13.14.3 Afimmune Biopharma Ltd NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)

13.14.4 Afimmune Biopharma Ltd Main Business Overview

13.14.5 Afimmune Biopharma Ltd Latest Developments

13.15 Zhejiang Doer Biologics Corp

13.15.1 Zhejiang Doer Biologics Corp Company Information

13.15.2 Zhejiang Doer Biologics Corp NASH Drug Pipeline Product Portfolios and Specifications

13.15.3 Zhejiang Doer Biologics Corp NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)

13.15.4 Zhejiang Doer Biologics Corp Main Business Overview

13.15.5 Zhejiang Doer Biologics Corp Latest Developments

13.16 Dicerna Pharmaceuticals Inc

13.16.1 Dicerna Pharmaceuticals Inc Company Information

13.16.2 Dicerna Pharmaceuticals Inc NASH Drug Pipeline Product Portfolios and Specifications

13.16.3 Dicerna Pharmaceuticals Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)

13.16.4 Dicerna Pharmaceuticals Inc Main Business Overview

13.16.5 Dicerna Pharmaceuticals Inc Latest Developments

13.17 ChemomAb Ltd

13.17.1 ChemomAb Ltd Company Information

13.17.2 ChemomAb Ltd NASH Drug Pipeline Product Portfolios and Specifications

13.17.3 ChemomAb Ltd NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)

13.17.4 ChemomAb Ltd Main Business Overview

13.17.5 ChemomAb Ltd Latest Developments

13.18 DURECT Corp

13.18.1 DURECT Corp Company Information

13.18.2 DURECT Corp NASH Drug Pipeline Product Portfolios and Specifications

13.18.3 DURECT Corp NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)

13.18.4 DURECT Corp Main Business Overview

13.18.5 DURECT Corp Latest Developments

13.19 Eli Lilly and Co

13.19.1 Eli Lilly and Co Company Information

13.19.2 Eli Lilly and Co NASH Drug Pipeline Product Portfolios and Specifications

13.19.3 Eli Lilly and Co NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)

13.19.4 Eli Lilly and Co Main Business Overview

13.19.5 Eli Lilly and Co Latest Developments

13.20 Enanta Pharmaceuticals Inc

13.20.1 Enanta Pharmaceuticals Inc Company Information

13.20.2 Enanta Pharmaceuticals Inc NASH Drug Pipeline Product Portfolios and Specifications

13.20.3 Enanta Pharmaceuticals Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)

13.20.4 Enanta Pharmaceuticals Inc Main Business Overview

13.20.5 Enanta Pharmaceuticals Inc Latest Developments

13.21 EncuraGen Inc

13.21.1 EncuraGen Inc Company Information

13.21.2 EncuraGen Inc NASH Drug Pipeline Product Portfolios and Specifications

13.21.3 EncuraGen Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)

13.21.4 EncuraGen Inc Main Business Overview

- 13.21.5 EncuraGen Inc Latest Developments
- 13.22 Engitix Ltd
 - 13.22.1 Engitix Ltd Company Information
 - 13.22.2 Engitix Ltd NASH Drug Pipeline Product Portfolios and Specifications
 - 13.22.3 Engitix Ltd NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.22.4 Engitix Ltd Main Business Overview
 - 13.22.5 Engitix Ltd Latest Developments
- 13.23 Heprotech Inc
 - 13.23.1 Heprotech Inc Company Information
 - 13.23.2 Heprotech Inc NASH Drug Pipeline Product Portfolios and Specifications
 - 13.23.3 Heprotech Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.23.4 Heprotech Inc Main Business Overview
 - 13.23.5 Heprotech Inc Latest Developments
- 13.24 Hinova Pharmaceuticals Inc
 - 13.24.1 Hinova Pharmaceuticals Inc Company Information
 - 13.24.2 Hinova Pharmaceuticals Inc NASH Drug Pipeline Product Portfolios and Specifications
 - 13.24.3 Hinova Pharmaceuticals Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.24.4 Hinova Pharmaceuticals Inc Main Business Overview
 - 13.24.5 Hinova Pharmaceuticals Inc Latest Developments
- 13.25 HK inno.N Corp
 - 13.25.1 HK inno.N Corp Company Information
 - 13.25.2 HK inno.N Corp NASH Drug Pipeline Product Portfolios and Specifications
 - 13.25.3 HK inno.N Corp NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.25.4 HK inno.N Corp Main Business Overview
 - 13.25.5 HK inno.N Corp Latest Developments
- 13.26 HotSpot Therapeutics Inc
 - 13.26.1 HotSpot Therapeutics Inc Company Information
 - 13.26.2 HotSpot Therapeutics Inc NASH Drug Pipeline Product Portfolios and Specifications
 - 13.26.3 HotSpot Therapeutics Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.26.4 HotSpot Therapeutics Inc Main Business Overview
 - 13.26.5 HotSpot Therapeutics Inc Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. NASH Drug Pipeline Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Table 2. NASH Drug Pipeline Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)

Table 3. Major Players of Protease Inhibitor

Table 4. Major Players of Immunomodulatory

Table 5. Major Players of Multiple Kinase Inhibitor

Table 6. Global NASH Drug Pipeline Sales by Type (2018-2023) & (K Units)

Table 7. Global NASH Drug Pipeline Sales Market Share by Type (2018-2023)

Table 8. Global NASH Drug Pipeline Revenue by Type (2018-2023) & (\$ million)

Table 9. Global NASH Drug Pipeline Revenue Market Share by Type (2018-2023)

Table 10. Global NASH Drug Pipeline Sale Price by Type (2018-2023) & (US\$/Unit)

Table 11. Global NASH Drug Pipeline Sales by Application (2018-2023) & (K Units)

Table 12. Global NASH Drug Pipeline Sales Market Share by Application (2018-2023)

Table 13. Global NASH Drug Pipeline Revenue by Application (2018-2023)

Table 14. Global NASH Drug Pipeline Revenue Market Share by Application (2018-2023)

Table 15. Global NASH Drug Pipeline Sale Price by Application (2018-2023) & (US\$/Unit)

Table 16. Global NASH Drug Pipeline Sales by Company (2018-2023) & (K Units)

Table 17. Global NASH Drug Pipeline Sales Market Share by Company (2018-2023)

Table 18. Global NASH Drug Pipeline Revenue by Company (2018-2023) (\$ Millions)

Table 19. Global NASH Drug Pipeline Revenue Market Share by Company (2018-2023)

Table 20. Global NASH Drug Pipeline Sale Price by Company (2018-2023) & (US\$/Unit)

Table 21. Key Manufacturers NASH Drug Pipeline Producing Area Distribution and Sales Area

Table 22. Players NASH Drug Pipeline Products Offered

Table 23. NASH Drug Pipeline Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

Table 24. New Products and Potential Entrants

Table 25. Mergers & Acquisitions, Expansion

Table 26. Global NASH Drug Pipeline Sales by Geographic Region (2018-2023) & (K Units)

Table 27. Global NASH Drug Pipeline Sales Market Share Geographic Region

(2018-2023)

Table 28. Global NASH Drug Pipeline Revenue by Geographic Region (2018-2023) & (\$ millions)

Table 29. Global NASH Drug Pipeline Revenue Market Share by Geographic Region (2018-2023)

Table 30. Global NASH Drug Pipeline Sales by Country/Region (2018-2023) & (K Units)

Table 31. Global NASH Drug Pipeline Sales Market Share by Country/Region (2018-2023)

Table 32. Global NASH Drug Pipeline Revenue by Country/Region (2018-2023) & (\$ millions)

Table 33. Global NASH Drug Pipeline Revenue Market Share by Country/Region (2018-2023)

Table 34. Americas NASH Drug Pipeline Sales by Country (2018-2023) & (K Units)

Table 35. Americas NASH Drug Pipeline Sales Market Share by Country (2018-2023)

Table 36. Americas NASH Drug Pipeline Revenue by Country (2018-2023) & (\$ Millions)

Table 37. Americas NASH Drug Pipeline Revenue Market Share by Country (2018-2023)

Table 38. Americas NASH Drug Pipeline Sales by Type (2018-2023) & (K Units)

Table 39. Americas NASH Drug Pipeline Sales by Application (2018-2023) & (K Units)

Table 40. APAC NASH Drug Pipeline Sales by Region (2018-2023) & (K Units)

Table 41. APAC NASH Drug Pipeline Sales Market Share by Region (2018-2023)

Table 42. APAC NASH Drug Pipeline Revenue by Region (2018-2023) & (\$ Millions)

Table 43. APAC NASH Drug Pipeline Revenue Market Share by Region (2018-2023)

Table 44. APAC NASH Drug Pipeline Sales by Type (2018-2023) & (K Units)

Table 45. APAC NASH Drug Pipeline Sales by Application (2018-2023) & (K Units)

Table 46. Europe NASH Drug Pipeline Sales by Country (2018-2023) & (K Units)

Table 47. Europe NASH Drug Pipeline Sales Market Share by Country (2018-2023)

Table 48. Europe NASH Drug Pipeline Revenue by Country (2018-2023) & (\$ Millions)

Table 49. Europe NASH Drug Pipeline Revenue Market Share by Country (2018-2023)

Table 50. Europe NASH Drug Pipeline Sales by Type (2018-2023) & (K Units)

Table 51. Europe NASH Drug Pipeline Sales by Application (2018-2023) & (K Units)

Table 52. Middle East & Africa NASH Drug Pipeline Sales by Country (2018-2023) & (K Units)

Table 53. Middle East & Africa NASH Drug Pipeline Sales Market Share by Country (2018-2023)

Table 54. Middle East & Africa NASH Drug Pipeline Revenue by Country (2018-2023) & (\$ Millions)

Table 55. Middle East & Africa NASH Drug Pipeline Revenue Market Share by Country

(2018-2023)

Table 56. Middle East & Africa NASH Drug Pipeline Sales by Type (2018-2023) & (K Units)

Table 57. Middle East & Africa NASH Drug Pipeline Sales by Application (2018-2023) & (K Units)

Table 58. Key Market Drivers & Growth Opportunities of NASH Drug Pipeline

Table 59. Key Market Challenges & Risks of NASH Drug Pipeline

Table 60. Key Industry Trends of NASH Drug Pipeline

Table 61. NASH Drug Pipeline Raw Material

Table 62. Key Suppliers of Raw Materials

Table 63. NASH Drug Pipeline Distributors List

Table 64. NASH Drug Pipeline Customer List

Table 65. Global NASH Drug Pipeline Sales Forecast by Region (2024-2029) & (K Units)

Table 66. Global NASH Drug Pipeline Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 67. Americas NASH Drug Pipeline Sales Forecast by Country (2024-2029) & (K Units)

Table 68. Americas NASH Drug Pipeline Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 69. APAC NASH Drug Pipeline Sales Forecast by Region (2024-2029) & (K Units)

Table 70. APAC NASH Drug Pipeline Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 71. Europe NASH Drug Pipeline Sales Forecast by Country (2024-2029) & (K Units)

Table 72. Europe NASH Drug Pipeline Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 73. Middle East & Africa NASH Drug Pipeline Sales Forecast by Country (2024-2029) & (K Units)

Table 74. Middle East & Africa NASH Drug Pipeline Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 75. Global NASH Drug Pipeline Sales Forecast by Type (2024-2029) & (K Units)

Table 76. Global NASH Drug Pipeline Revenue Forecast by Type (2024-2029) & (\$ Millions)

Table 77. Global NASH Drug Pipeline Sales Forecast by Application (2024-2029) & (K Units)

Table 78. Global NASH Drug Pipeline Revenue Forecast by Application (2024-2029) & (\$ Millions)

Table 79. Intercept Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors

Table 80. Intercept NASH Drug Pipeline Product Portfolios and Specifications

Table 81. Intercept NASH Drug Pipeline Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 82. Intercept Main Business

Table 83. Intercept Latest Developments

Table 84. Genfit Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors

Table 85. Genfit NASH Drug Pipeline Product Portfolios and Specifications

Table 86. Genfit NASH Drug Pipeline Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 87. Genfit Main Business

Table 88. Genfit Latest Developments

Table 89. Allergan Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors

Table 90. Allergan NASH Drug Pipeline Product Portfolios and Specifications

Table 91. Allergan NASH Drug Pipeline Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 92. Allergan Main Business

Table 93. Allergan Latest Developments

Table 94. Madrigal Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors

Table 95. Madrigal NASH Drug Pipeline Product Portfolios and Specifications

Table 96. Madrigal NASH Drug Pipeline Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 97. Madrigal Main Business

Table 98. Madrigal Latest Developments

Table 99. Immuron Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors

Table 100. Immuron NASH Drug Pipeline Product Portfolios and Specifications

Table 101. Immuron NASH Drug Pipeline Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 102. Immuron Main Business

Table 103. Immuron Latest Developments

Table 104. Galectin Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors

Table 105. Galectin NASH Drug Pipeline Product Portfolios and Specifications

Table 106. Galectin NASH Drug Pipeline Sales (K Units), Revenue (\$ Million), Price

(US\$/Unit) and Gross Margin (2018-2023)

Table 107. Galectin Main Business

Table 108. Galectin Latest Developments

Table 109. Gilead Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors

Table 110. Gilead NASH Drug Pipeline Product Portfolios and Specifications

Table 111. Gilead NASH Drug Pipeline Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 112. Gilead Main Business

Table 113. Gilead Latest Developments

Table 114. 89bio Inc Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors

Table 115. 89bio Inc NASH Drug Pipeline Product Portfolios and Specifications

Table 116. 89bio Inc NASH Drug Pipeline Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 117. 89bio Inc Main Business

Table 118. 89bio Inc Latest Developments

Table 119. ABIONYX Pharma SA Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors

Table 120. ABIONYX Pharma SA NASH Drug Pipeline Product Portfolios and Specifications

Table 121. ABIONYX Pharma SA NASH Drug Pipeline Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 122. ABIONYX Pharma SA Main Business

Table 123. ABIONYX Pharma SA Latest Developments

Table 124. Abivax SA Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors

Table 125. Abivax SA NASH Drug Pipeline Product Portfolios and Specifications

Table 126. Abivax SA NASH Drug Pipeline Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 127. Abivax SA Main Business

Table 128. Abivax SA Latest Developments

Table 129. Abliva AB Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors

Table 130. Abliva AB NASH Drug Pipeline Product Portfolios and Specifications

Table 131. Abliva AB NASH Drug Pipeline Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 132. Abliva AB Main Business

Table 133. Abliva AB Latest Developments

Table 134. Acquist Therapeutics Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 135. Acquist Therapeutics NASH Drug Pipeline Product Portfolios and Specifications
Table 136. Acquist Therapeutics NASH Drug Pipeline Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
Table 137. Acquist Therapeutics Main Business
Table 138. Acquist Therapeutics Latest Developments
Table 139. AdAlta Ltd Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 140. AdAlta Ltd NASH Drug Pipeline Product Portfolios and Specifications
Table 141. AdAlta Ltd NASH Drug Pipeline Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
Table 142. AdAlta Ltd Main Business
Table 143. AdAlta Ltd Latest Developments
Table 144. Afimmune Biopharma Ltd Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 145. Afimmune Biopharma Ltd NASH Drug Pipeline Product Portfolios and Specifications
Table 146. Afimmune Biopharma Ltd NASH Drug Pipeline Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
Table 147. Afimmune Biopharma Ltd Main Business
Table 148. Afimmune Biopharma Ltd Latest Developments
Table 149. Zhejiang Doer Biologics Corp Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 150. Zhejiang Doer Biologics Corp NASH Drug Pipeline Product Portfolios and Specifications
Table 151. Zhejiang Doer Biologics Corp NASH Drug Pipeline Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
Table 152. Zhejiang Doer Biologics Corp Main Business
Table 153. Zhejiang Doer Biologics Corp Latest Developments
Table 154. Dicerna Pharmaceuticals Inc Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 155. Dicerna Pharmaceuticals Inc NASH Drug Pipeline Product Portfolios and Specifications
Table 156. Dicerna Pharmaceuticals Inc NASH Drug Pipeline Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
Table 157. Dicerna Pharmaceuticals Inc Main Business
Table 158. Dicerna Pharmaceuticals Inc Latest Developments

Table 159. ChemomAb Ltd Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors

Table 160. ChemomAb Ltd NASH Drug Pipeline Product Portfolios and Specifications

Table 161. ChemomAb Ltd NASH Drug Pipeline Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 162. ChemomAb Ltd Main Business

Table 163. ChemomAb Ltd Latest Developments

Table 164. DURECT Corp Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors

Table 165. DURECT Corp NASH Drug Pipeline Product Portfolios and Specifications

Table 166. DURECT Corp NASH Drug Pipeline Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 167. DURECT Corp Main Business

Table 168. DURECT Corp Latest Developments

Table 169. Eli Lilly and Co Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors

Table 170. Eli Lilly and Co NASH Drug Pipeline Product Portfolios and Specifications

Table 171. Eli Lilly and Co NASH Drug Pipeline Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 172. Eli Lilly and Co Main Business

Table 173. Eli Lilly and Co Latest Developments

Table 174. Enanta Pharmaceuticals Inc Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors

Table 175. Enanta Pharmaceuticals Inc NASH Drug Pipeline Product Portfolios and Specifications

Table 176. Enanta Pharmaceuticals Inc NASH Drug Pipeline Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 177. Enanta Pharmaceuticals Inc Main Business

Table 178. Enanta Pharmaceuticals Inc Latest Developments

Table 179. EncuraGen Inc Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors

Table 180. EncuraGen Inc NASH Drug Pipeline Product Portfolios and Specifications

Table 181. EncuraGen Inc NASH Drug Pipeline Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 182. EncuraGen Inc Main Business

Table 183. EncuraGen Inc Latest Developments

Table 184. Engitix Ltd Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors

Table 185. Engitix Ltd NASH Drug Pipeline Product Portfolios and Specifications

Table 186. Engitix Ltd NASH Drug Pipeline Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 187. Engitix Ltd Main Business

Table 188. Engitix Ltd Latest Developments

Table 189. Heprotech Inc Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors

Table 190. Heprotech Inc NASH Drug Pipeline Product Portfolios and Specifications

Table 191. Heprotech Inc NASH Drug Pipeline Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 192. Heprotech Inc Main Business

Table 193. Heprotech Inc Latest Developments

Table 194. Hinova Pharmaceuticals Inc Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors

Table 195. Hinova Pharmaceuticals Inc NASH Drug Pipeline Product Portfolios and Specifications

Table 196. Hinova Pharmaceuticals Inc NASH Drug Pipeline Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 197. Hinova Pharmaceuticals Inc Main Business

Table 198. Hinova Pharmaceuticals Inc Latest Developments

Table 199. HK inno.N Corp Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors

Table 200. HK inno.N Corp NASH Drug Pipeline Product Portfolios and Specifications

Table 201. HK inno.N Corp NASH Drug Pipeline Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 202. HK inno.N Corp Main Business

Table 203. HK inno.N Corp Latest Developments

Table 204. HotSpot Therapeutics Inc Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors

Table 205. HotSpot Therapeutics Inc NASH Drug Pipeline Product Portfolios and Specifications

Table 206. HotSpot Therapeutics Inc NASH Drug Pipeline Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 207. HotSpot Therapeutics Inc Main Business

Table 208. HotSpot Therapeutics Inc Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of NASH Drug Pipeline
- Figure 2. NASH Drug Pipeline Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global NASH Drug Pipeline Sales Growth Rate 2018-2029 (K Units)
- Figure 7. Global NASH Drug Pipeline Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. NASH Drug Pipeline Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of Protease Inhibitor
- Figure 10. Product Picture of Immunomodulatory
- Figure 11. Product Picture of Multiple Kinase Inhibitor
- Figure 12. Global NASH Drug Pipeline Sales Market Share by Type in 2022
- Figure 13. Global NASH Drug Pipeline Revenue Market Share by Type (2018-2023)
- Figure 14. NASH Drug Pipeline Consumed in Clinical
- Figure 15. Global NASH Drug Pipeline Market: Clinical (2018-2023) & (K Units)
- Figure 16. NASH Drug Pipeline Consumed in Academic Research
- Figure 17. Global NASH Drug Pipeline Market: Academic Research (2018-2023) & (K Units)
- Figure 18. Global NASH Drug Pipeline Sales Market Share by Application (2022)
- Figure 19. Global NASH Drug Pipeline Revenue Market Share by Application in 2022
- Figure 20. NASH Drug Pipeline Sales Market by Company in 2022 (K Units)
- Figure 21. Global NASH Drug Pipeline Sales Market Share by Company in 2022
- Figure 22. NASH Drug Pipeline Revenue Market by Company in 2022 (\$ Million)
- Figure 23. Global NASH Drug Pipeline Revenue Market Share by Company in 2022
- Figure 24. Global NASH Drug Pipeline Sales Market Share by Geographic Region (2018-2023)
- Figure 25. Global NASH Drug Pipeline Revenue Market Share by Geographic Region in 2022
- Figure 26. Americas NASH Drug Pipeline Sales 2018-2023 (K Units)
- Figure 27. Americas NASH Drug Pipeline Revenue 2018-2023 (\$ Millions)
- Figure 28. APAC NASH Drug Pipeline Sales 2018-2023 (K Units)
- Figure 29. APAC NASH Drug Pipeline Revenue 2018-2023 (\$ Millions)
- Figure 30. Europe NASH Drug Pipeline Sales 2018-2023 (K Units)
- Figure 31. Europe NASH Drug Pipeline Revenue 2018-2023 (\$ Millions)
- Figure 32. Middle East & Africa NASH Drug Pipeline Sales 2018-2023 (K Units)

Figure 33. Middle East & Africa NASH Drug Pipeline Revenue 2018-2023 (\$ Millions)

Figure 34. Americas NASH Drug Pipeline Sales Market Share by Country in 2022

Figure 35. Americas NASH Drug Pipeline Revenue Market Share by Country in 2022

Figure 36. Americas NASH Drug Pipeline Sales Market Share by Type (2018-2023)

Figure 37. Americas NASH Drug Pipeline Sales Market Share by Application (2018-2023)

Figure 38. United States NASH Drug Pipeline Revenue Growth 2018-2023 (\$ Millions)

Figure 39. Canada NASH Drug Pipeline Revenue Growth 2018-2023 (\$ Millions)

Figure 40. Mexico NASH Drug Pipeline Revenue Growth 2018-2023 (\$ Millions)

Figure 41. Brazil NASH Drug Pipeline Revenue Growth 2018-2023 (\$ Millions)

Figure 42. APAC NASH Drug Pipeline Sales Market Share by Region in 2022

Figure 43. APAC NASH Drug Pipeline Revenue Market Share by Regions in 2022

Figure 44. APAC NASH Drug Pipeline Sales Market Share by Type (2018-2023)

Figure 45. APAC NASH Drug Pipeline Sales Market Share by Application (2018-2023)

Figure 46. China NASH Drug Pipeline Revenue Growth 2018-2023 (\$ Millions)

Figure 47. Japan NASH Drug Pipeline Revenue Growth 2018-2023 (\$ Millions)

Figure 48. South Korea NASH Drug Pipeline Revenue Growth 2018-2023 (\$ Millions)

Figure 49. Southeast Asia NASH Drug Pipeline Revenue Growth 2018-2023 (\$ Millions)

Figure 50. India NASH Drug Pipeline Revenue Growth 2018-2023 (\$ Millions)

Figure 51. Australia NASH Drug Pipeline Revenue Growth 2018-2023 (\$ Millions)

Figure 52. China Taiwan NASH Drug Pipeline Revenue Growth 2018-2023 (\$ Millions)

Figure 53. Europe NASH Drug Pipeline Sales Market Share by Country in 2022

Figure 54. Europe NASH Drug Pipeline Revenue Market Share by Country in 2022

Figure 55. Europe NASH Drug Pipeline Sales Market Share by Type (2018-2023)

Figure 56. Europe NASH Drug Pipeline Sales Market Share by Application (2018-2023)

Figure 57. Germany NASH Drug Pipeline Revenue Growth 2018-2023 (\$ Millions)

Figure 58. France NASH Drug Pipeline Revenue Growth 2018-2023 (\$ Millions)

Figure 59. UK NASH Drug Pipeline Revenue Growth 2018-2023 (\$ Millions)

Figure 60. Italy NASH Drug Pipeline Revenue Growth 2018-2023 (\$ Millions)

Figure 61. Russia NASH Drug Pipeline Revenue Growth 2018-2023 (\$ Millions)

Figure 62. Middle East & Africa NASH Drug Pipeline Sales Market Share by Country in 2022

Figure 63. Middle East & Africa NASH Drug Pipeline Revenue Market Share by Country in 2022

Figure 64. Middle East & Africa NASH Drug Pipeline Sales Market Share by Type (2018-2023)

Figure 65. Middle East & Africa NASH Drug Pipeline Sales Market Share by Application (2018-2023)

Figure 66. Egypt NASH Drug Pipeline Revenue Growth 2018-2023 (\$ Millions)

Figure 67. South Africa NASH Drug Pipeline Revenue Growth 2018-2023 (\$ Millions)

Figure 68. Israel NASH Drug Pipeline Revenue Growth 2018-2023 (\$ Millions)

Figure 69. Turkey NASH Drug Pipeline Revenue Growth 2018-2023 (\$ Millions)

Figure 70. GCC Country NASH Drug Pipeline Revenue Growth 2018-2023 (\$ Millions)

Figure 71. Manufacturing Cost Structure Analysis of NASH Drug Pipeline in 2022

Figure 72. Manufacturing Process Analysis of NASH Drug Pipeline

Figure 73. Industry Chain Structure of NASH Drug Pipeline

Figure 74. Channels of Distribution

Figure 75. Global NASH Drug Pipeline Sales Market Forecast by Region (2024-2029)

Figure 76. Global NASH Drug Pipeline Revenue Market Share Forecast by Region (2024-2029)

Figure 77. Global NASH Drug Pipeline Sales Market Share Forecast by Type (2024-2029)

Figure 78. Global NASH Drug Pipeline Revenue Market Share Forecast by Type (2024-2029)

Figure 79. Global NASH Drug Pipeline Sales Market Share Forecast by Application (2024-2029)

Figure 80. Global NASH Drug Pipeline Revenue Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global NASH Drug Pipeline Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/GDAF1654569CEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GDAF1654569CEN.html>